Liposome-Embedding Silicon Microparticle for Oxaliplatin Delivery in Tumor Chemotherapy.

colon cancer liposome mesoporous silicon microparticle multistage vector nanoparticle oxaliplatin

Journal

Pharmaceutics
ISSN: 1999-4923
Titre abrégé: Pharmaceutics
Pays: Switzerland
ID NLM: 101534003

Informations de publication

Date de publication:
17 Jun 2020
Historique:
received: 29 04 2020
revised: 05 06 2020
accepted: 12 06 2020
entrez: 21 6 2020
pubmed: 21 6 2020
medline: 21 6 2020
Statut: epublish

Résumé

Mesoporous silicon microparticles (MSMPs) can incorporate drug-carrying nanoparticles (NPs) into their pores. An NP-loaded MSMP is a multistage vector (MSV) that forms a Matryoshka-like structure that protects the therapeutic cargo from degradation and prevents its dilution in the circulation during delivery to tumor cells. We developed an MSV constituted by 1 µm discoidal MSMPs embedded with PEGylated liposomes containing oxaliplatin (oxa) which is a therapeutic agent for colorectal cancer (CRC). To obtain extra-small liposomes able to fit the 60 nm pores of MSMP, we tested several liposomal formulations, and identified two optimal compositions, with a prevalence of the rigid lipid 1,2-distearoyl-sn-glycero-3-phosphocholine and of 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-[methoxy(polyethylene glycol)-2000]. To improve the MSV assembly, we optimized the liposome-loading inside the MSMP and achieved a five-fold increase of the payload using an innovative lyophilization approach. This procedure also increased the load and limited dimensional changes of the liposomes released from the MSV in vitro. Lastly, we found that the cytotoxic efficacy of oxa-loaded liposomes and-oxa-liposome-MSV in CRC cell culture was similar to that of free oxa. This study increases knowledge about extra-small liposomes and their loading into porous materials and provides useful hints about alternative strategies for designing drug-encapsulating NPs.

Identifiants

pubmed: 32560359
pii: pharmaceutics12060559
doi: 10.3390/pharmaceutics12060559
pmc: PMC7355455
pii:
doi:

Types de publication

Journal Article

Langues

eng

Subventions

Organisme : Ministero della Salute
ID : RF-2010-23183729
Organisme : Regione Campania
ID : "Sviluppo di Approcci Terapeutici INnovativi per patologie neoplastiche resistenti ai trattamenti (SATIN)", POR Campania FESR 2014/2020
Organisme : Ministero dell'Istruzione, dell'Università e della Ricerca
ID : FAR 2017, University of Chieti - Pescara "G. d'Annunzio", Chieti, Italy.
Organisme : Ministero dell'Istruzione, dell'Università e della Ricerca
ID : "Fondo di finanziamento per le attività base di ricerca" (FFABR) 2017

Références

Dalton Trans. 2018 May 15;47(19):6645-6653
pubmed: 29632935
Biomaterials. 2013 Nov;34(33):8469-77
pubmed: 23911070
Neuropharmacology. 2015 Oct;97:289-305
pubmed: 26044641
J Pharm Sci. 2014 Jul;103(7):2177-2183
pubmed: 24846075
Biomaterials. 2018 Jun;167:205-215
pubmed: 29571055
J Biomed Mater Res A. 2014 Oct;102(10):3540-9
pubmed: 25269799
Adv Funct Mater. 2012 Oct 23;22(20):4225-4235
pubmed: 23227000
J Control Release. 2012 Feb 28;158(1):148-55
pubmed: 22062689
Drug Dev Ind Pharm. 2005 Jan;31(2):223-9
pubmed: 15773289
Nanoscale. 2017 Apr 20;9(16):5329-5341
pubmed: 28398453
Eur J Cancer. 2003 Jan;39(1):112-9
pubmed: 12504667
Cancer Res. 2010 May 1;70(9):3687-96
pubmed: 20430760
J Nanosci Nanotechnol. 2011 Feb;11(2):1259-66
pubmed: 21456169
Small. 2013 May 27;9(9-10):1722-33
pubmed: 23255523
Pharmacol Res. 2010 Aug;62(2):57-89
pubmed: 20045055
Int J Nanomedicine. 2018 Sep 11;13:5301-5320
pubmed: 30254436
Sci Rep. 2016 Oct 05;6:34422
pubmed: 27703233
J Control Release. 2009 Jul 1;137(1):8-14
pubmed: 19285528
Nat Biotechnol. 2015 Sep;33(9):941-51
pubmed: 26348965
Adv Healthc Mater. 2016 Apr 20;5(8):936-46
pubmed: 26890862
Methods Enzymol. 2012;508:109-30
pubmed: 22449923
Nat Nanotechnol. 2008 Mar;3(3):151-7
pubmed: 18654487
Theranostics. 2014 Feb 15;4(5):487-97
pubmed: 24672582
Prog Mol Biol Transl Sci. 2011;104:1-52
pubmed: 22093216
Chem Commun (Camb). 2012 Mar 7;48(20):2630-2
pubmed: 22286522
Curr Drug Targets. 2015;16(13):1540-7
pubmed: 25382209
J Colloid Interface Sci. 2005 May 1;285(1):110-7
pubmed: 15797403
Eur J Pharm Biopharm. 2018 Jun;127:432-442
pubmed: 29605467
Biochim Biophys Acta. 2008 Dec;1778(12):2749-56
pubmed: 18762164
Prog Nucl Magn Reson Spectrosc. 2013 Feb;69:1-22
pubmed: 23465641
Biochimie. 2012 Jan;94(1):2-10
pubmed: 21839138
J Drug Target. 2018 Apr;26(4):311-318
pubmed: 28797169
Invest New Drugs. 2011 Dec;29(6):1321-7
pubmed: 20658169
Nat Rev Cancer. 2017 Jan;17(1):20-37
pubmed: 27834398
Trends Biotechnol. 2010 Apr;28(4):181-8
pubmed: 20079548
J Control Release. 2015 Dec 10;219:406-415
pubmed: 26264836
CA Cancer J Clin. 2019 Jan;69(1):7-34
pubmed: 30620402
Planta Med. 2017 Mar;83(5):482-491
pubmed: 27542175
Clin Cancer Res. 2013 Apr 1;19(7):1806-15
pubmed: 23386691
Curr Drug Deliv. 2007 Jan;4(1):89-101
pubmed: 17269921
ACS Nano. 2013 Nov 26;7(11):9867-80
pubmed: 24131405
Int J Mol Sci. 2018 Nov 13;19(11):
pubmed: 30428564
Proteomics Clin Appl. 2017 May;11(5-6):
pubmed: 28019089
J Control Release. 2018 Feb 28;272:72-82
pubmed: 29325699
Acc Chem Res. 2011 Oct 18;44(10):979-89
pubmed: 21902173
Nanomedicine (Lond). 2015 Jul;10(12):1923-40
pubmed: 26139126
Chemphyschem. 2010 Apr 6;11(5):1029-35
pubmed: 20162656
Biochim Biophys Acta. 1992 Aug 19;1127(3):249-54
pubmed: 1511002
Nat Nanotechnol. 2013 Jan;8(1):61-8
pubmed: 23241654
Eur J Pharm Sci. 2000 Oct;11 Suppl 2:S81-91
pubmed: 11033430
Colloids Surf B Biointerfaces. 2019 Mar 1;175:469-476
pubmed: 30572155
J Control Release. 2015 Feb 10;199:106-13
pubmed: 25499917
Cancer Lett. 2013 Jul 1;334(2):245-52
pubmed: 22858582
Adv Mater. 2011 Sep 22;23(36):H278-82
pubmed: 21833996
J Pharm Biomed Anal. 2018 Sep 10;159:192-199
pubmed: 29990886
J Control Release. 2015 Nov 10;217:263-72
pubmed: 26381900
Adv Drug Deliv Rev. 2011 Mar 18;63(3):129-30
pubmed: 20457195
Mol Ther. 2016 May;24(5):849-51
pubmed: 27198852
Nat Rev Clin Oncol. 2018 Feb;15(2):77-78
pubmed: 29182161
Adv Drug Deliv Rev. 2016 Apr 1;99(Pt A):28-51
pubmed: 26456916
Nat Biotechnol. 2016 Apr;34(4):414-8
pubmed: 26974511
J Mater Chem B. 2017 Jan 14;5(2):207-219
pubmed: 28670454
Nature. 2005 Dec 1;438(7068):590-6
pubmed: 16319878
Eur J Lipid Sci Technol. 2011 Oct;113(10):1174-1187
pubmed: 22164124
Curr Drug Targets. 2015;16(14):1612-22
pubmed: 26601721
Biomaterials. 2016 Mar;82:168-77
pubmed: 26761780

Auteurs

Armando Cevenini (A)

Dipartimento di Medicina Molecolare e Biotecnologie Mediche, Università degli Studi di Napoli "Federico II", 80131 Napoli, Italy.
CEINGE-Biotecnologie Avanzate S.c.a r.l., 80145 Napoli, Italy.

Christian Celia (C)

Department of Pharmacy, University of Chieti-Pescara "G. d'Annuzio", 66100 Chieti, Italy.
Department of Nanomedicine, Houston Methodist Research Institute, Houston, TX 77030, USA.

Stefania Orrù (S)

CEINGE-Biotecnologie Avanzate S.c.a r.l., 80145 Napoli, Italy.
Dipartimento di Scienze Motorie e del Benessere, Università "Parthenope", 80133 Napoli, Italy.
IRCCS SDN, 80143 Napoli, Italy.

Daniela Sarnataro (D)

Dipartimento di Medicina Molecolare e Biotecnologie Mediche, Università degli Studi di Napoli "Federico II", 80131 Napoli, Italy.

Maddalena Raia (M)

CEINGE-Biotecnologie Avanzate S.c.a r.l., 80145 Napoli, Italy.

Valentina Mollo (V)

Italian Institute of Technology@CRIB Center for Advanced Biomaterials for Health Care, 80125 Napoli, Italy.

Marcello Locatelli (M)

Department of Pharmacy, University of Chieti-Pescara "G. d'Annuzio", 66100 Chieti, Italy.

Esther Imperlini (E)

IRCCS SDN, 80143 Napoli, Italy.

Nicoletta Peluso (N)

Dipartimento di Medicina Molecolare e Biotecnologie Mediche, Università degli Studi di Napoli "Federico II", 80131 Napoli, Italy.
CEINGE-Biotecnologie Avanzate S.c.a r.l., 80145 Napoli, Italy.

Rosa Peltrini (R)

Dipartimento di Medicina Molecolare e Biotecnologie Mediche, Università degli Studi di Napoli "Federico II", 80131 Napoli, Italy.
CEINGE-Biotecnologie Avanzate S.c.a r.l., 80145 Napoli, Italy.
Department of Respiratory Sciences, College of Life Sciences, University of Leicester, Leicester LE1 7RH, UK.

Enrica De Rosa (E)

Department of Nanomedicine, Houston Methodist Research Institute, Houston, TX 77030, USA.

Alessandro Parodi (A)

IRCCS SDN, 80143 Napoli, Italy.
Institute of Molecular Medicine, Sechenov First Moscow State Medical University, 119991 Moscow, Russia.

Luigi Del Vecchio (L)

Dipartimento di Medicina Molecolare e Biotecnologie Mediche, Università degli Studi di Napoli "Federico II", 80131 Napoli, Italy.
CEINGE-Biotecnologie Avanzate S.c.a r.l., 80145 Napoli, Italy.

Luisa Di Marzio (L)

Department of Pharmacy, University of Chieti-Pescara "G. d'Annuzio", 66100 Chieti, Italy.

Massimo Fresta (M)

Department of Health Sciences, University "Magna Græcia" of Catanzaro, Campus Universitario "S. Venuta", I-88100 Catanzaro, Italy.

Paolo Antonio Netti (PA)

Italian Institute of Technology@CRIB Center for Advanced Biomaterials for Health Care, 80125 Napoli, Italy.
Department of Chemical, Materials & Industrial Production Engineering, University of Naples Federico II, 80125 Naples, Italy.

Haifa Shen (H)

Department of Nanomedicine, Houston Methodist Research Institute, Houston, TX 77030, USA.
Department of Cell and Developmental Biology, Weill Cornell Medicine, New York, NY 10065, USA.

Xuewu Liu (X)

Department of Nanomedicine, Houston Methodist Research Institute, Houston, TX 77030, USA.

Ennio Tasciotti (E)

CEINGE-Biotecnologie Avanzate S.c.a r.l., 80145 Napoli, Italy.
Center for Biomimetic Medicine, Houston Methodist Research Institute (HMRI), Houston, TX 77030, USA.
Houston Methodist Orthopedics & Sports Medicine, Houston Methodist Hospital, Houston, TX 77030, USA.

Francesco Salvatore (F)

Dipartimento di Medicina Molecolare e Biotecnologie Mediche, Università degli Studi di Napoli "Federico II", 80131 Napoli, Italy.
CEINGE-Biotecnologie Avanzate S.c.a r.l., 80145 Napoli, Italy.

Classifications MeSH